Compare GLRE & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLRE | TOI |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Cayman Islands | United States |
| Employees | N/A | 641 |
| Industry | Property-Casualty Insurers | Medical/Nursing Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.9M | 497.9M |
| IPO Year | 2007 | N/A |
| Metric | GLRE | TOI |
|---|---|---|
| Price | $15.52 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 147.0K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | $30.15 |
| Revenue Next Year | N/A | $25.77 |
| P/E Ratio | $86.89 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $2.32 |
| 52 Week High | $19.39 | $6.67 |
| Indicator | GLRE | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 48.50 |
| Support Level | $14.78 | $4.90 |
| Resistance Level | $17.05 | $5.63 |
| Average True Range (ATR) | 0.57 | 0.37 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 32.88 | 26.71 |
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.